Chapter 5 192 References 1. Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thor Oncol. 2016;11:39-51. 2. Peters, S., Reck, M., Smit, E.F., Mok, T.S., Hellman, M.D. How to make best use of immunotherapy as first-line treatment for advanced/metastatic non-small cell lung cancer? Ann Oncol. 2019; March 26. 3. Gettinger, S, et al. Five year follow up of nivolumab in previously treated advanced nonsmall-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36:1675-1684. 4. Garon, E.B. et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the Keynote 001 study. J Clin Oncol. 2019; 37(28):2518-2527. 5. Garon, E.B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. New Eng J Med. 2015;372:2018-2028. 6. Sun, R. et al. A radiomics approach to assess tumor-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19;1180-1191. 7. Hellmann, M. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 2018;33:843-852. 8. Duruisseaux, M. et al. Epigenetic prediction of response to anti-PD-1 treatment in nonsmall-cell lung cancer: a multicenter, retrospective analysis. Lancet Respir Med. 2018;6:771781. 9. Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:197. 10. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373(20):123-35. 11. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39. 12. Gregorc, V. et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarkerstratified, randomized phase 3 trial. Lancet Oncology. 2014;15:713-721. 13. Tsypin, M., Asmellash, S., Meyer, K., Touchet, B., Roder, H. Extending the information content of the MALDI analysis of biological fluids via multi-million shot analysis. PLoS ONE 14(12): e0226012. 14. Weber, J.S. et al. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. Cancer Immunol Res. 2018;6:79-86. 15. Ascierto, P.A. et al. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. J Immunother Cancer. 2019;7:91. 16. Roder, J. et al. A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data. BMC Bioinformatics. 2019;20:325. 17. Goodfellow, I., Bengio, Y., Courville, A. Deep Learning. Cambridge: MIT Press; 2016. p.5-11. 18. Breiman, L. Out-of-bag estimation. Technical Report. Department of Statistics, University of California, 1996.
RkJQdWJsaXNoZXIy MTk4NDMw